View Clinical Trial (Medical Research Study)
Pharmacogenomics for Antidepressant Guidance and Education
| City: |
|
Boston |
| State: |
|
Massachusetts |
| Zip Code: |
|
02114 |
| Conditions: |
|
Treatment Resistant Depression |
| Purpose: |
|
More than one out of three individuals treated for major depressive disorder (MDD) do not
experience a full reduction of symptoms even when treated with adequate antidepressant
medication. These individuals may have treatment-resistant depression. This is a condition
that contributes to the tremendous costs of MDD, in terms of health care costs, functional
impairment (limitation of an individual's functional ability), and diminished quality of
life.
There is a clear need for personalized medicine, for people at high risk for
treatment-resistant depression. If these individuals could be identified early in the course
of their depression, they could be recommended for more intensive or specialized
interventions. Doing so could improve their likelihood of having a full reduction in their
symptoms.
Today, there are many treatment options for MDD. Individuals can spend months or years in
and out of treatment before receiving one that works for their treatment-resistant
depression.
The investigators want to study treatment resistant depression by examining specific genes
(genotyping) that might influence how your body responds to certain antidepressant
medications. This process of examining specific genes is not experimental. To look at your
specific genes, the investigators will collect a saliva sample. Genes contain the material
passed from parent to child that determines the make-up of the body and mind. For example,
some genes control the color of your hair or eyes. Genes are contained in your DNA
(deoxyribonucleic acid). There are many differences in DNA, from one person to another.
These differences may affect a person's chances of having a particular disease.
|
| Study Summary: |
|
This will be a 6-month, randomized, controlled study of assay-guided treatment (AGT) versus
treatment as usual (TAU) in adult inpatients with major depressive disorder. Two hundred
subjects will be randomized to receive AGT or TAU. After subjects are screened, determined
to be eligible, and complete baseline assessments, saliva samples for assay will be obtained
from all subjects. However, only those subjects that are randomized to the AGT arm will have
the saliva samples immediately analyzed. Subjects in the TAU arm will have their saliva
samples stored for future GWAS analysis.
Once the saliva samples are obtained, the attending psychiatrists will be asked to indicate
their top three choices of antidepressants and at what doses they will initiate treatment.
In order to prevent delays in providing treatments, the first choice antidepressants will be
started prior to receiving assay results.
Upon receiving the assay reports (AGT arm), the attending psychiatrists will be asked
whether the reports influenced their choice of antidepressant treatments and doses of
antidepressants, as well as their confidence in their choices. The attending psychiatrists
will then document any switches in antidepressant treatments or changes in doses of current
antidepressant medications on a structured form. The assay reports will be available
between 3 to 5 days after the saliva samples are taken. The attending psychiatrists who are
randomized to be provided the results of CYP genotyping will also be provided a phone number
for consultation with Genomind Labs regarding the interpretation of the results.
Trough antidepressant blood samples for the AGT arm (10-12 hours after last dose) for
therapeutic drug monitoring (TDM) will be obtained within 24 hours of discharge. Blood
samples will also be obtained from the TAU arm, but they will be stored for future analysis
of CYP genotyping and biomarker analysis of treatment resistant MDD. Clinical follow-up will
proceed as felt to be clinically indicated. For subjects who have been discharged before the
assay results are received, the attending psychiatrists will complete the from indicating
changes in treatments as if patients were still in hospital. Results and recommendations
will be forwarded to the identified outpatient psychiatrists.
The AGT arm is not standard care for patients with depression. The addition of
assay-results and questionnaires makes the AGT arm different than standard care. Only the
questionnaires make the TAU arm different than standard care.
Note:
Within 24 hours after you are admitted to the Inpatient Psychiatric Unit, the "baseline"
assessment will occur. If you stay in the Inpatient Psychiatric Unit for more than one week,
the "weekly" assessment will occur every 7 days. Typically, patients spend an average of
8-10 days in the Inpatient Psychiatric Unit. The day before or the day of your discharge
from the Inpatient Psychiatric Unit, your "discharge" assessment will occur. One, 3, and 6
months after you are discharged, you will be asked to complete follow-up assessments.
|
| Criteria: |
|
Inclusion Criteria:
- Age 18-70
- Written informed consent
- Meets DSM-IV criteria in the Structured Clinical Interview for DSM-IV-TR (SCID-I/P)17
and the MINI for current major depressive disorder, without psychotic features
- QIDS-SR score of at least 10 (i.e., moderate depression) at initial visit
- Failure of at least 1 prior adequate trial of a standard antidepressant (i.e., 6
weeks at adequate dose), assessed by the Antidepressant Treatment History
Questionnaire (ATRQ)18 criteria
- Inpatient and expected to remain so for 5 or more days
- Hospitalized within past 72 hours
Exclusion Criteria:
- Pregnant women or women of child bearing potential who are not using a medically
accepted means of contraception (to include oral contraceptive or implant, condom,
diaphragm, spermicide, intrauterine device, tubal ligation, or partner with
vasectomy). Immediately after the pregnancy test, women with positive pregnancy tests
will be unable to enroll in the study
- Women who are breastfeeding
- Patients who have taken an investigational psychotropic drug within the last 3 months
- Section 12 status (involuntary admission)
|
| NCT ID: |
|
NCT01555021 |
| Primary Contact: |
|
Principal Investigator
John D Matthews, MD
Massachusetts General Hospital
John D Matthews, MD
Phone: 6177249144
Email: jmatthews@partners.org
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Boston, Massachusetts 02114
United States
John D Matthews, MD
Phone: 617-724-9144
Email: jmatthews@partners.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|